Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06601309 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

Study acronym: ESCC
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated September 15, 2025 (before its estimated July 1, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Secondary endpoints: 6 to 7v2
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study aims to evaluate the impact of the neoadjuvant treatment strategy based on CPS score on the pathological complete response (pCR) rate in patients with resectable locally advanced esophageal cancer.
Trial Details
NCT Number NCT06601309
Lead Sponsor Fujian Medical University Union Hospital
Conditions
(from sponsor)		 Esophageal Squamous Cell Carcinoma
Related terms Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma
Enrollment 90 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov